Bayer Gets Positive Results in Atrial Fibrillation Drug Trial
April 04 2022 - 2:44AM
Dow Jones News
By Cecilia Butini
Bayer AG said late Sunday that it got positive results from a
Phase 2b trial studying asundexian, a drug meant to prevent
bleeding in patients with atrial fibrillation--an irregular and
often very rapid heart rhythm (arrhythmia) that can lead to blood
clots in the heart--who are also at risk of stroke.
The drug could have the potential to prevent thromboembolic
events without increasing the risk of bleeding in patients,
according to Bayer.
The company said that the trial evaluated asundexian with
another drug, called apixaban. Asundexian hasn't yet been approved
for use in any country, Bayer said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 04, 2022 02:29 ET (06:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024
